Evaluating approaches to patents and pharmaceutical test data protection in selected Southern African Development Community (SADC) member states

Abstract

A discussion of pharmaceutical test data protection is a potentially broad area for scholarly investigation. During preclinical and clinical drug testing, test data that evidences safety, effectiveness, and quality is generated to obtain marketing approval by drug regulatory authorities. Depending on the nature of the information and the jurisdiction, such information may be protected as a trade secret or a patent. Protecting patents and pharmaceutical test data in the SADC has significant ethical, legal, and social implications (ELSI). While it is essential to incentivise research and development, it is also crucial to ensure that patients have access to safe and effective medicines and that the public interest is protected. SADC members have diverse approaches and laws on patents and pharmaceutical test data protection. While some countries have comprehensive legal frameworks that balance intellectual property rights with the public interest, others have outdated or incomplete frameworks. The lack or inadequacy of legal frameworks for patents and pharmaceutical test data protection in some SADC countries can negatively affect public health. This paper surveys and calibrates the existing legal frameworks within the SADC region by identifying gaps and suggesting possible law reform solutions inspired by the Trade Related Aspects of Intellectual Property (TRIPS) Agreement, other international frameworks, and comparative law. Using the reward theory as its theoretical lens and linking the main arguments to the obligation of patentees to disclose their inventions fully, the paper concludes that the SADC region requires adequate legal frameworks.

Keywords: {'name': 'Pharmaceutical Test Data, Patents, SADC, Drugs, Public Health, Reward Theory, Health Research Ethics'}

Authors & affiliations

Lonias Ndlovu
Affiliation not supplied

Deposited references

Supplied references, not a list of publications citing this article.

DOI: 10.1007/s40319-012-0016-z

Armouti, W., & Nsour, M. F. (2016). Test data protection: Different approaches and implementation in pharmaceuticals. Marquette Intellectual Property Law Review, 20, 267.

Ashok, A. (2019). Test data protection within Indian IP regime. Cochin University Law Review, forthcoming.

DOI: 10.1001/jama.2016.2420

DOI: 10.1111/j.1747-1796.2002.tb00190.x

DOI: 10.1007/978-3-031-29436-5

Chakrabarti, G. (2023). Need of data exclusivity: Impact on access to medicine. Journal of Intellectual Property Rights, 19, 325–336.

Childs, D. W. (2005). The World Health Organization's prequalification program and its potential effect on data exclusivity laws. Food and Drug Law Journal, 60, 79–97.

DOI: 10.1007/978-3-030-83114-1

Daigle, B. (2021). Data protection laws in Africa: A pan-African survey and noted trends. Journal of International Commerce and Economics, 1.

DOI: 10.2139/ssrn.2648770

DOI: 10.1111/dewb.12105

DOI: 10.22459/PIP.06.2016

Dratler Jr, J., & McJohn, S. M. (2023). Intellectual property law: Commercial, creative and industrial property. Law Journal Press.

DOI: 10.17159/1727-3781/2018/v21i0a2004

Durkin, A., Maria, P. A. S., Willmore, B., & Kapczynski, A. (2021). Addressing the risks that trade secret protections pose for health and rights. Health and Human Rights, 23, 129.

DOI: 10.1016/j.phrs.2018.01.024

DOI: 10.1007/s11019-021-10060-1

DOI: 10.18601/16571959.n30.01

Kamwendo, T. A. (2016). A critical discussion on Botswana's access to medicine and TRIPS flexibilities. [Unpublished manuscript].

Knapp, C. L., Crystal, N. M., Prince, H. G., Hart, D. K., & Silverstein, J. M. (2023). Problems in contract law: Cases and materials. Aspen Publishing.

Lemley, M. A., Merges, R. P., & Balganesh, S. (2020). Intellectual property in the new technological age: Volume I. Clause 8 Publishing.

DOI: 10.1016/j.cct.2014.01.001

Malik, M. (2022). The ethical implications of the TRIPS Agreement. [Unpublished manuscript].

DOI: 10.2139/ssrn.4507044

DOI: 10.1017/lst.2022.43

DOI: 10.17159/obiter.v37i3.11523

Owoeye, O. A. (2014). Data exclusivity and public health under the TRIPS agreement. Journal of Law, Information and Science, 23, 106–133.

Pashikanti, S., & Koribilli, N. (2021). Generic drug registration requirements in RoW countries. Journal of Pharmaceutical Sciences and Research, 13, 617–622.

Pfumorodze, J. (2011). The WTO TRIPs agreement and access to medicine in Southern Africa. University of Botswana Law Journal, 13, 87.

Ray, D. (2021). Critical analysis of John Rawls' theory of distributive justice. Jus Corpus Law Journal, 2, 10.

DOI: 10.1093/jlb/lsaa010

DOI: 10.1596/1813-9450-5228

DOI: 10.1111/jwip.12093

DOI: 10.17159/1727-3781/2021/v24i0a10420

DOI: 10.1007/978-3-030-83114-1_7

DOI: 10.7554/eLife.16931

DOI: 10.30875/00344762-en